Notable healthcare headlines for the week: Eli Lilly, Merck and Becton, Dickinson in focus
Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.
Merck & Co. Inc. stock underperforms Thursday when compared to competitors
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
STAT3d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
Merck Is Suffering From a Classic Pharma Problem
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Merck beats estimates on Q4 earnings, stock slides on tepid 2025 guidance
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, although the drug company’s outlook for 2025 ...
Merck: Don't Fight The Tape, How Low Can It Go?
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.